XML 29 R7.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Capital Surplus
Retained Earnings
Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2022   52,954,985      
Beginning balance at Dec. 31, 2022 $ 1,383,176 $ 530 $ 1,222,761 $ 303,146 $ (143,261)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 130,497     130,497  
Other comprehensive income (loss) 25,174       25,174
Cash dividends declared (27,698)     (27,698)  
Common stock issued in connection with the exercise of stock options and restricted stock awards (in shares)   336,094      
Common stock issued in connection with the exercise of stock options and restricted stock awards (76) $ 3 (79)    
Stock-based compensation expense 9,945   9,945    
Ending balance (in shares) at Dec. 31, 2023   53,291,079      
Ending balance at Dec. 31, 2023 1,521,018 $ 533 1,232,627 405,945 (118,087)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 115,003     115,003  
Other comprehensive income (loss) (7,277)       (7,277)
Cash dividends declared (28,308)     (28,308)  
Common stock issued in connection with the exercise of stock options and restricted stock awards (in shares)   246,520      
Common stock issued in connection with the exercise of stock options and restricted stock awards (498) $ 2 (500)    
Repurchase of common stock (in shares)   (108,900)      
Repurchase of common stock (2,842) $ (1) (2,841)    
Stock-based compensation expense $ 10,764   10,764    
Ending balance (in shares) at Dec. 31, 2024 53,428,699 53,428,699      
Ending balance at Dec. 31, 2024 $ 1,607,860 $ 534 1,240,050 492,640 (125,364)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 102,872     102,872  
Other comprehensive income (loss) 52,399       52,399
Cash dividends declared (29,296)     (29,296)  
Common stock issued in connection with the exercise of stock options and restricted stock awards (in shares)   116,296      
Common stock issued in connection with the exercise of stock options and restricted stock awards (980) $ 1 (981)    
Repurchase of common stock (in shares)   (2,642,971)      
Repurchase of common stock (73,352) $ (26) (73,326)    
Stock-based compensation expense $ 9,151   9,151    
Ending balance (in shares) at Dec. 31, 2025 50,902,024 50,902,024      
Ending balance at Dec. 31, 2025 $ 1,668,654 $ 509 $ 1,174,894 $ 566,216 $ (72,965)